Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study-Reference-Cited by-同舟云学术

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Published:2022-10 Issue: Volume:Volume 15 Page:2245-2252
ISSN:1178-7015
Container-title:Clinical, Cosmetic and Investigational Dermatology
language:en
Short-container-title:CCID

Author:

Li Ying,Lu Jia-Jing,Zhong Xiao-Yuan,Yu Ying-Yuan,Yu Ning,Wang Yu,Yi Xue-Mei,Ding Yang-Feng,Shi Yu-Ling^ORCID

Publisher

Informa UK Limited

Subject

Polymers and Plastics,General Environmental Science

Reference20 articles.

1. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

2. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

5. Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study;Journal of Dermatological Treatment;2024-05-20

2. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States;Journal of Dermatological Treatment;2024-05-15

3. Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China;Dermatology and Therapy;2024-05

4. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

5. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study;Experimental Dermatology;2023-10-21